How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) Services Market
- By Therapy Type: Gene Therapy, Cell Therapy, Tissue Engineered Products, Somatic Cell Therapy, Gene-Modified Cell Therapy
- By Service Type: Process Development, Analytical Development, GMP Manufacturing, Quality Control and Assurance, Regulatory Support
- By Manufacturing Scale: Clinical-Scale Manufacturing, Commercial-Scale Manufacturing, Pilot-Scale Manufacturing
- By Technology Platform: Viral Vector Manufacturing, Non-Viral Vector Manufacturing, Autologous Cell Processing, Allogeneic Cell Processing, 3D Bioprinting
- By Client Type: Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutions, Contract Research Organizations
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Gene Therapy leads By Therapy Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.181 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.189 →
Full report · locked preview
Everything inside the Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) Services Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Therapy Type 5
Service Type 5
Manufacturing Scale 3
Technology Platform 5
Client Type 4
Companies profiled
Lonza Group
Catalent Inc.
Thermo Fisher Scientific
WuXi AppTec
Samsung Biologics
Cytiva (part of Danaher Corporation)
Fujifilm Diosynth Biotechnologies
AGC Biologics
Boehringer Ingelheim BioXcellence
Sartorius Stedim Biotech
CordenPharma
Brammer Bio (a Catalent company)
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Lonza Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Catalent Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →WuXi AppTec
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Samsung Biologics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Cytiva (part of Danaher Corporation)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Fujifilm Diosynth Biotechnologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →AGC Biologics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Boehringer Ingelheim BioXcellence
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sartorius Stedim Biotech
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →CordenPharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Brammer Bio (a Catalent company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Vivebiotech
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →KBI Biopharma
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Oxford Biomedica
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,008M by 2033 · 5.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Gene Therapy55.9
- Cell Therapy8.6
- Tissue Engineered Products14.1
- Somatic Cell Therapy9.6
- Gene-Modified Cell Therapy11.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$222.5M → $326.9M · 4.9%
Europe$155.1M → $210.0M · 3.9%
Asia Pacific$141.6M → $209.9M · 5.0%
Latin America$87.7M → $143.7M · 6.4%
Middle East and Africa$67.4M → $96.4M · 4.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.112026
5.132027
5.142028
5.152029
5.152030
5.172031
5.182032
5.192033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Lonza Group11.0
- Catalent Inc.22.9
- Thermo Fisher Scientific7.4
- WuXi AppTec10.6
- Samsung Biologics11.8
- Cytiva (part of Danaher Corporation)8.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapy Type26.3%
Service Type18.9%
Manufacturing Scale22.3%
Technology Platform9.9%
Client Type22.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.1
- Europe21.3
- Asia Pacific21.3
- Latin America14.6
- Middle East and Africa9.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Lonza Group | 76 | 97 | 82 | 96 | 88 | 83 | 87 |
| Catalent Inc. | 84 | 75 | 92 | 81 | 86 | 89 | 85 |
| Thermo Fisher Scientific | 83 | 80 | 76 | 65 | 82 | 64 | 75 |
| WuXi AppTec | 78 | 69 | 62 | 58 | 73 | 74 | 69 |
| Samsung Biologics | 57 | 65 | 61 | 62 | 59 | 60 | 61 |
| Cytiva (part of Danaher Corporation) | 63 | 53 | 63 | 69 | 66 | 61 | 63 |
| Fujifilm Diosynth Biotechnologies | 50 | 46 | 61 | 65 | 55 | 66 | 57 |
| AGC Biologics | 48 | 49 | 46 | 52 | 60 | 35 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Lonza Group
- Catalent Inc.
- Thermo Fisher Scientific
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Lonza Group | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Catalent Inc. | ✓ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Thermo Fisher Scientific | ✓ | ◐ | ◐ | − | ◐ | − |
| WuXi AppTec | ✓ | ◐ | − | ◐ | ◐ | ◐ |
| Samsung Biologics | ◐ | ✓ | ◐ | ◐ | ◐ | − |
| Cytiva (part of Danaher Corporation) | ◐ | − | ◐ | ◐ | ◐ | − |
| Fujifilm Diosynth Biotechnologies | − | − | ◐ | ◐ | − | − |
| AGC Biologics | − | − | ◐ | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Lonza Group87
2Catalent Inc.85
3Thermo Fisher Scientific75
4WuXi AppTec69
5Cytiva (part of Danaher Corporation)63
6Samsung Biologics61
7Fujifilm Diosynth Biotechnologies57
8AGC Biologics48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Lonza GroupCatalent Inc.
Challenger2
Strong scale, closing on the leaders.
Thermo Fisher ScientificWuXi AppTec
Contender3
Focused players with pockets of strength.
Samsung BiologicsCytiva (part of Danaher Corporation)Fujifilm Diosynth Biotechnologies
Niche1
Specialists in a single segment or region.
AGC Biologics
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapy Type in North America, then scale across Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) Services Market — a $220M beachhead inside a $4.01B market.
Beachhead (SOM)$220Mobtainable near-term
Serviceable (SAM)$1.38Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Gene Therapy
Best fit — highest urgency & budget in Therapy Type.
Economic buyer76 fit
Cell Therapy
Strong fit — clear ROI and a fast path to value.
End user68 fit
Tissue Engineered Products
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapy Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Service Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Manufacturing Scale
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve20%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Therapy Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) Services Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified22%
Evaluation14%
Closed-won5%
$17.7KCAC
$65KLTV
3.7:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) Services Market is a high-growth opportunity — $2.24B by 2033, compounding at 10.1%.
TAM · 2025$1.04Btoday
TAM · 2033$2.24Bforecast
CAGR10.1%2027–2033
Cumulative$14.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.24BTotal addressable market
SAM$853MServiceable available market
SOM$147MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.1% CAGR
Demand compounds through 2033, outpacing GDP across Therapy Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapy Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.24BLarge & growingTAM by 2033 at 10.1% CAGR
$853MServiceable nowreachable with today’s model
$147MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.75BBear6.6% CAGR
$2.24BBase10.1% CAGR
$2.87BBull13.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Service Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) Services Market — a $2.59B market by 2033. Plan: grow share from 7.6% to 13.0%.
Market size · 2033$2.59Btotal addressable
Market CAGR8.5%2027–2033
Target share13.0%from 7.6% today
Revenue ambition$337Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.6% | 13.0% | On track |
| Revenue | $203M | $337M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 31.7% | 42.7% | On track |
| Customer retention | 86.2% | 94.6% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapy Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Service Type capability
A defensible second engine — invest in Service Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapy Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Service Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $35M capacity & capability investment
- Greenlight bolt-on M&A in Service Type
- Authorise North America expansion plan
- Fund R&D program for Therapy Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskBehind
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) Services Market conversation — a $1.15B market you can size, segment and defend in minutes.
Market size · 2033$1.15Btotal opportunity
Growth4.8%CAGR to 2033
Addressable buyers1,009+accounts in scope
Typical ROI5.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapy Type
Goal Grow share in Therapy Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.3×return on cost, year one
< 3 mopayback period
$81K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Lonza GroupCatalent Inc.Thermo Fisher ScientificWuXi AppTecSamsung BiologicsCytiva (part of Danaher Corporation)Fujifilm Diosynth BiotechnologiesAGC Biologics+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) Services Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) Services Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Advanced Therapy Based on Gene Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportHeart Disease Insurance Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportElectronic Data Capture Software Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportAdvanced Surgical Imaging System Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportAdvanced Sterilization Product Market
Market size, share, segmentation and regional forecast.
$827M market · 2025 base year
View reportBiopharmaceutical Cold Chain Transport Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportBiopharmaceutical Transport Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportAdvanced Sports Medicine Product Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportAdvanced Silver Wound Dressing Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportChild Nutrition Monitoring and Data Analysis Software Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportAdvanced Securement Dressing Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportAdvanced Scar Gel Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.